» Articles » PMID: 32945843

VEGF-B Is an Autocrine Gliotrophic Factor for Müller Cells Under Pathologic Conditions

Overview
Specialty Ophthalmology
Date 2020 Sep 18
PMID 32945843
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Müller glia are important in retinal health and disease and are a major source of retinal VEGF-A. Of the different VEGF family members, the role of VEGF-A in retinal health and disease has been studied extensively. The potential contribution of other VEGF family members to retinal pathophysiology, however, remains poorly defined. This study aimed to understand the role of VEGF-B in Müller cell pathophysiology.

Methods: The expression of different VEGFs and their receptors in human MIO-M1 and mouse QMMuC-1 Müller cell lines and primary murine Müller cells was examined by RT-PCR, ELISA, and Western blot. The effect of recombinant VEGF-B or VEGF-B neutralization on Müller cell viability and survival under normal, hypoxic, and oxidative (4-hydroxynonenal [4-HNE]) conditions was evaluated by Alamar Blue, Yo-Pro uptake, and immunocytochemistry. The expression of glial fibrillary acidic protein, aquaporin-4, inward rectifying K+ channel subtype 4.1, glutamine synthetase, and transient receptor potential vanilloid 4 under different treatment conditions was examined by RT-PCR, immunocytochemistry, and Western blot. Transient receptor potential vanilloid 4 channel activity was assessed using a Fura-2-based calcium assay.

Results: VEGF-B was expressed in Müller cells at the highest levels compared with other members of the VEGF family. VEGF-B neutralization did not affect Müller cell viability or functionality under normal conditions, but enhanced hypoxia- or 4-HNE-induced Müller cell death and decreased inward rectifying K+ channel subtype 4.1 and aquaporin-4 expression. Recombinant VEGF-B restored Müller cell glutamine synthetase expression under hypoxic conditions and protected Müller cells from 4-HNE-induced damage by normalizing transient receptor potential vanilloid 4 channel expression and activity.

Conclusions: Autocrine production of VEGF-B protects Müller cells under pathologic conditions.

Citing Articles

Glial cell alterations in diabetes-induced neurodegeneration.

Llorian-Salvador M, Cabeza-Fernandez S, Gomez-Sanchez J, de la Fuente A Cell Mol Life Sci. 2024; 81(1):47.

PMID: 38236305 PMC: 10796438. DOI: 10.1007/s00018-023-05024-y.


Hyperlipidemia and lipid-lowering therapy in diabetic retinopathy (DR): A bibliometric study and visualization analysis in 1993-2023.

Tan H, Fu X, Chen Y, Wang Y, Chen D Heliyon. 2023; 9(10):e21109.

PMID: 37916126 PMC: 10616351. DOI: 10.1016/j.heliyon.2023.e21109.


IL-33 regulates Müller cell-mediated retinal inflammation and neurodegeneration in diabetic retinopathy.

Augustine J, Pavlou S, Harkin K, Stitt A, Xu H, Chen M Dis Model Mech. 2023; 16(9).

PMID: 37671525 PMC: 10499035. DOI: 10.1242/dmm.050174.


Aldehyde Dehydrogenase and Aldo-Keto Reductase Enzymes: Basic Concepts and Emerging Roles in Diabetic Retinopathy.

Karan B, Little K, Augustine J, Stitt A, Curtis T Antioxidants (Basel). 2023; 12(7).

PMID: 37508004 PMC: 10376360. DOI: 10.3390/antiox12071466.


Vascular Endothelial Growth Factor Ligands and Receptors in Breast Cancer.

Brogowska K, Zajkowska M, Mroczko B J Clin Med. 2023; 12(6).

PMID: 36983412 PMC: 10056253. DOI: 10.3390/jcm12062412.


References
1.
Mohamedali K, Poblenz A, Sikes C, Navone N, Thorpe P, Darnay B . Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Res. 2006; 66(22):10919-28. DOI: 10.1158/0008-5472.CAN-06-0459. View

2.
Bry M, Kivela R, Leppanen V, Alitalo K . Vascular endothelial growth factor-B in physiology and disease. Physiol Rev. 2014; 94(3):779-94. DOI: 10.1152/physrev.00028.2013. View

3.
Huang D, Zhao C, Ju R, Kumar A, Tian G, Huang L . VEGF-B inhibits hyperglycemia- and Macugen-induced retinal apoptosis. Sci Rep. 2016; 6:26059. PMC: 4870690. DOI: 10.1038/srep26059. View

4.
Gu L, Xu H, Zhang C, Yang Q, Zhang L, Zhang J . Time-dependent changes in hypoxia- and gliosis-related factors in experimental diabetic retinopathy. Eye (Lond). 2018; 33(4):600-609. PMC: 6461831. DOI: 10.1038/s41433-018-0268-z. View

5.
Caballero B, Sherman S, Falk T . Insights into the Mechanisms Involved in Protective Effects of VEGF-B in Dopaminergic Neurons. Parkinsons Dis. 2017; 2017:4263795. PMC: 5394414. DOI: 10.1155/2017/4263795. View